235 related articles for article (PubMed ID: 28143559)
1. Health utilities using SF-6D scores in Japanese patients with chronic hepatitis C treated with sofosbuvir-based regimens in clinical trials.
Younossi Z; Stepanova M; Omata M; Mizokami M; Walters M; Hunt S
Health Qual Life Outcomes; 2017 Jan; 15(1):25. PubMed ID: 28143559
[TBL] [Abstract][Full Text] [Related]
2. Quality of life of Japanese patients with chronic hepatitis C treated with ledipasvir and sofosbuvir.
Younossi ZM; Stepanova M; Omata M; Mizokami M; Walters M; Hunt S
Medicine (Baltimore); 2016 Aug; 95(33):e4243. PubMed ID: 27537553
[TBL] [Abstract][Full Text] [Related]
3. Sofosbuvir and ledipasvir are associated with high sustained virologic response and improvement of health-related quality of life in East Asian patients with hepatitis C virus infection.
Younossi ZM; Stepanova M; Henry L; Han KH; Ahn SH; Lim YS; Chuang WL; Kao JH; Nguyen KV; Lai CL; Chan HL; Wei L
J Viral Hepat; 2018 Dec; 25(12):1429-1437. PubMed ID: 29974665
[TBL] [Abstract][Full Text] [Related]
4. Treatment of hepatitis C virus recurrence after transplantation with sofosbuvir/ledipasvir: The role of ribavirin.
Globke B; Raschzok N; Teegen EM; Pratschke J; Schott E; Eurich D
Transpl Infect Dis; 2017 Feb; 19(1):. PubMed ID: 27943544
[TBL] [Abstract][Full Text] [Related]
5. Patient-reported Outcomes in Asian Patients With Chronic Hepatitis C Treated With Ledipasvir and Sofosbuvir.
Younossi ZM; Stepanova M; Chan HLY; Lee MH; Yu ML; Dan YY; Choi MS; Henry L
Medicine (Baltimore); 2016 Mar; 95(9):e2702. PubMed ID: 26945356
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Ledipasvir/Sofosbuvir with and without Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: a meta-analysis.
Tao T; Jiang X; Chen Y; Song Y
Int J Infect Dis; 2017 Feb; 55():56-71. PubMed ID: 28040553
[TBL] [Abstract][Full Text] [Related]
7. Sofosbuvir and ledipasvir improve patient-reported outcomes in patients co-infected with hepatitis C and human immunodeficiency virus.
Younossi ZM; Stepanova M; Sulkowski M; Naggie S; Henry L; Hunt S
J Viral Hepat; 2016 Nov; 23(11):857-865. PubMed ID: 27291391
[TBL] [Abstract][Full Text] [Related]
8. Ledipasvir/sofosbuvir treatment of hepatitis C virus is associated with reduction in serum apolipoprotein levels.
Younossi ZM; Elsheikh E; Stepanova M; Gerber L; Nader F; Stamm LM; Brainard DM; McHutchinson JG
J Viral Hepat; 2015 Dec; 22(12):977-82. PubMed ID: 26280786
[TBL] [Abstract][Full Text] [Related]
9. The patient's journey with chronic hepatitis C from interferon plus ribavirin to interferon- and ribavirin-free regimens: a study of health-related quality of life.
Younossi ZM; Stepanova M; Nader F; Lam B; Hunt S
Aliment Pharmacol Ther; 2015 Aug; 42(3):286-95. PubMed ID: 26059536
[TBL] [Abstract][Full Text] [Related]
10. Patients' preferences and health utility assessment with SF-6D and EQ-5D in patients with chronic hepatitis C treated with sofosbuvir regimens.
Stepanova M; Nader F; Cure S; Bourhis F; Hunt S; Younossi ZM
Aliment Pharmacol Ther; 2014 Sep; 40(6):676-85. PubMed ID: 25040192
[TBL] [Abstract][Full Text] [Related]
11. Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens.
Wyles D; Pockros P; Morelli G; Younes Z; Svarovskaia E; Yang JC; Pang PS; Zhu Y; McHutchison JG; Flamm S; Lawitz E
Hepatology; 2015 Jun; 61(6):1793-7. PubMed ID: 25846014
[TBL] [Abstract][Full Text] [Related]
12. Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: Results from the ION-1, -2, and -3 clinical trials.
Younossi ZM; Stepanova M; Marcellin P; Afdhal N; Kowdley KV; Zeuzem S; Hunt SL
Hepatology; 2015 Jun; 61(6):1798-808. PubMed ID: 25627448
[TBL] [Abstract][Full Text] [Related]
13. Adherence to treatment of chronic hepatitis C: from interferon containing regimens to interferon and ribavirin free regimens.
Younossi ZM; Stepanova M; Henry L; Nader F; Younossi Y; Hunt S
Medicine (Baltimore); 2016 Jul; 95(28):e4151. PubMed ID: 27428205
[TBL] [Abstract][Full Text] [Related]
14. The impact of ledipasvir/sofosbuvir on patient-reported outcomes in cirrhotic patients with chronic hepatitis C: the SIRIUS study.
Younossi ZM; Stepanova M; Pol S; Bronowicki JP; Carrieri MP; Bourlière M
Liver Int; 2016 Jan; 36(1):42-8. PubMed ID: 26059860
[TBL] [Abstract][Full Text] [Related]
15. The Efficacy and Safety of 12 Weeks of Sofosbuvir and Ledipasvir versus Sofosbuvir, Ledipasvir, and Ribavirin in Patients with Chronic Hepatitis C, Genotype 1, Who Have Cirrhosis and Have Failed Prior Therapy: A Systematic Review and Meta-Analysis.
Stokes W; Fenton C; Clement F; James M; Ronksley P; Tang KL
Can J Gastroenterol Hepatol; 2017; 2017():6468309. PubMed ID: 28367429
[No Abstract] [Full Text] [Related]
16. Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials.
Alqahtani SA; Afdhal N; Zeuzem S; Gordon SC; Mangia A; Kwo P; Fried M; Yang JC; Ding X; Pang PS; McHutchison JG; Pound D; Reddy KR; Marcellin P; Kowdley KV; Sulkowski M
Hepatology; 2015 Jul; 62(1):25-30. PubMed ID: 25963890
[TBL] [Abstract][Full Text] [Related]
17. Cost-utility analysis of ledipasvir/sofosbuvir for the treatment of genotype 1 chronic hepatitis C in Japan.
Igarashi A; Tang W; Guerra I; Marié L; Cure S; Lopresti M
Curr Med Res Opin; 2017 Jan; 33(1):11-21. PubMed ID: 27609424
[TBL] [Abstract][Full Text] [Related]
18. Patient-Reported Outcomes of Elderly Adults with Chronic Hepatitis C Treated with Interferon- and Ribavirin-Free Regimens.
Younossi ZM; Stepanova M; Nader F; Henry L
J Am Geriatr Soc; 2016 Feb; 64(2):386-93. PubMed ID: 26825683
[TBL] [Abstract][Full Text] [Related]
19. Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis.
Reddy KR; Bourlière M; Sulkowski M; Omata M; Zeuzem S; Feld JJ; Lawitz E; Marcellin P; Welzel TM; Hyland R; Ding X; Yang J; Knox S; Pang P; Dvory-Sobol H; Subramanian GM; Symonds W; McHutchison JG; Mangia A; Gane E; Mizokami M; Pol S; Afdhal N
Hepatology; 2015 Jul; 62(1):79-86. PubMed ID: 25846144
[TBL] [Abstract][Full Text] [Related]
20. The levels of monoamine neurotransmitters and measures of mental and emotional health in HCV patients treated with ledipasvir (LDV) and sofosbuvir (SOF) with or without ribavirin (RBV).
Golabi P; Elsheikh E; Karrar A; Estep JM; Younossi I; Stepanova M; Gerber L; Younossi ZM
Medicine (Baltimore); 2016 Nov; 95(46):e5066. PubMed ID: 27861337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
